Overview

Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM.
Phase:
Phase 1
Details
Lead Sponsor:
CellMed AG, a subsidiary of BTG plc.